NAT-ERLOTINIB
Identification of Nat-Erlotinib
| No description |
Google image searchProduct monograph
Active ingredient
erlotinib (erlotinib hydrochloride), 25 MG
DIN: 02483912
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: NATCO PHARMA (CANADA) INC
Date: 08-MAY-2019
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EB — Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (ATC, ATC/DDD)
- L01EB02 — ERLOTINIB (ATC/DDD)
Reference brand drug: Tarceva
